Savara Management
Management criteria checks 3/4
Savara's CEO is Matt Pauls, appointed in Sep 2020, has a tenure of 3.67 years. total yearly compensation is $3.76M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $2.33M. The average tenure of the management team and the board of directors is 2.7 years and 7.1 years respectively.
Key information
Matt Pauls
Chief executive officer
US$3.8m
Total compensation
| CEO salary percentage | 15.8% |
| CEO tenure | 3.7yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.7yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?
Dec 14
Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Feb 16Is Savara (NASDAQ:SVRA) Using Too Much Debt?
Oct 12Savara's rare lung disorder drug gets promising innovative medicine status in UK
Aug 26Savara GAAP EPS of -$0.06 in-line
Aug 11Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?
Jan 24Is Savara (NASDAQ:SVRA) A Risky Investment?
Jul 05Savara: They Failed Once, But They Are Trying Again
Jun 07The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares
Mar 17Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares
Feb 26Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex
Nov 24Savara EPS misses by $0.01
Nov 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$64m |
| Dec 31 2023 | US$4m | US$595k | -US$55m |
| Sep 30 2023 | n/a | n/a | -US$49m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$40m |
| Dec 31 2022 | US$2m | US$580k | -US$38m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$2m | US$560k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$45m |
| Jun 30 2021 | n/a | n/a | -US$46m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$2m | US$170k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$68m |
| Jun 30 2020 | n/a | n/a | -US$69m |
| Mar 31 2020 | n/a | n/a | -US$81m |
| Dec 31 2019 | US$64k | n/a | -US$78m |
| Sep 30 2019 | n/a | n/a | -US$57m |
| Jun 30 2019 | n/a | n/a | -US$57m |
| Mar 31 2019 | n/a | n/a | -US$47m |
| Dec 31 2018 | US$114k | n/a | -US$62m |
| Sep 30 2018 | n/a | n/a | -US$58m |
| Jun 30 2018 | n/a | n/a | -US$52m |
| Mar 31 2018 | n/a | n/a | -US$53m |
| Dec 31 2017 | US$75k | n/a | -US$31m |
Compensation vs Market: Matt's total compensation ($USD3.76M) is about average for companies of similar size in the US market ($USD3.40M).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
CEO
Matt Pauls (52 yo)
3.7yrs
Tenure
US$3,759,723
Compensation
Mr. Matthew Pauls, J.D. M.B.A. also known as Matt, is Director at NVN Liquidation Inc. He serves as Director of Soleno Therapeutics, Inc. since August 15, 2023. He serves as Chief Executive Officer at Sava...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 3.7yrs | US$3.76m | 0.37% $ 2.3m | |
| CFO, Chief Administrative Officer & Secretary | 7.5yrs | US$1.52m | 0.060% $ 378.0k | |
| Chief Operating Officer | 1.3yrs | US$2.66m | 0% $ 0 | |
| Senior VP & General Counsel | 6.2yrs | no data | no data | |
| Chief Business Officer | 3.6yrs | no data | 0.084% $ 530.5k | |
| Head of Clinical Operations | 3yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs & Quality Assurance | 2.8yrs | no data | no data | |
| Executive Vice President of Global Technical Operations | 2.7yrs | no data | no data | |
| Chief Medical Officer | 1.5yrs | US$698.69k | 0.0072% $ 45.9k | |
| Executive Vice President of Global Commercial | 1.3yrs | no data | no data | |
| Senior VP of Global Medical Affairs | 1.1yrs | no data | no data | |
| Senior VP & Head of Clinical Development | less than a year | no data | no data |
2.7yrs
Average Tenure
55yo
Average Age
Experienced Management: SVRA's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 7.1yrs | US$3.76m | 0.37% $ 2.3m | |
| Independent Director | 7.1yrs | US$158.13k | 1.59% $ 10.1m | |
| Lead Independent Director | 10.6yrs | US$155.13k | 0.12% $ 772.7k | |
| Independent Director | 13.6yrs | US$149.13k | 0.0092% $ 58.5k | |
| Independent Director | 15.3yrs | US$157.63k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 4.4yrs | US$144.63k | 0% $ 0 | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 4.4yrs | US$155.63k | 0% $ 0 | |
| Member of Clinical Advisory Board | 3.3yrs | no data | no data | |
| Member of Clinical advisory Board | 1.3yrs | no data | no data |
7.1yrs
Average Tenure
58yo
Average Age
Experienced Board: SVRA's board of directors are considered experienced (7.1 years average tenure).